NCT07767630RecruitingEarly phase 1
Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma
An Exploratory Proof-of-Concept (POC) Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Fractionated Dosing of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma (Including a Run-in Phase)
Source: ClinicalTrials.gov · Last updated 21 Aug 2026
Brief summary (registry, in English)
Fractionated dosing of \[211At\]MABG Radiotherapy in Relapsed/Refractory Neuroblastoma
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 12 Aug 2026
- Start date
- 21 Jul 2026
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Sichuan University
- Diseases
- Neuroblastoma, Childhood cancers
- NCT number
- NCT07767630
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 10
- From 21 Jul 2026 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Antibody-based immunotherapy within fewer than 5 half-lives or 30 days (whichever is shorter), or who have not yet recovered from adverse effects of any biologic therapy.
- Treatment with \[¹³¹I\]MIBG or Lu177 targeted radionuclide therapy less than 3 months of last administration.
- Autologous stem cell transplant \<12 weeks, or Allogeneic stem cell transplant \<4 months (patients \>4 months post-transplant must be free of active GVHD).
- Radiotherapy within 2 weeks prior to the first study dose (However, patients with a single-site irradiation that remains MIBG avid may be enrolled.) or extensive-field radiotherapy (e.g., craniospinal, whole abdomen, whole lung, or \>50% of bone marrow area) within 12 weeks prior to the first study dose.
Other illness
- Renal Insufficiency.
- Active Infections.
Who the study is looking for
- Patients diagnosed with MIBG avid lesions, high-risk neuroblastoma per the Revised International Neuroblastoma Response Criteria (Revised INRC), with refractory, relapsed, or progressive disease.
- All measurable soft tissue lesions must be MIBG-avid.
- Age ≥ 1 year at enrollment.
- Lansky performance status ≥ 50%.
- Adequate organ function and hematologic parameters.
Age in the registry: 1 year to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| West China Hospital Coordinator of this site? Confirm its status | Chengdu | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.